Considering your experience with Sharlife so far, how likely are you to recommend us to a friend or colleague?
Not at all likelyExtremely likely
(Optional)
Wuxi Biologics (Cayman) Inc.
2269Health technology
$17.5B
Market Cap
Shariah Analysis
Passed
Business
Cash
Liabilities
Based on AAOIFI screening standards, Wuxi Biologics (Cayman) Inc. appears to be Passed.
Business Activity
FYE 2024
Non-Permissible Income (<5%)0.00%
Non-Permissible
-
Total Income
$18.7K
Revenue Breakdown
Pre-IND services
$7.1K
Early-phase (phases I & II) services
$3.8K
Late-phase (phase III) services and commercial manufacturing
$7.5K
Others (sales of other biologics products, biologics purification medium and chromatographic column)
$325
Financial Screening
FYE 2024
Cash (<30%)16.20%
Non-Shariah Cash Items
Cash And Cash Equivalents$8.3B
Other Short Term Investments$2.4B
Hedging Assets Current-
Restricted Cash$13.9M
Liabilities (<30%)7.46%
Non-Shariah Liabilities
Current Capital Lease Obligation$183.7M
Long Term Debt$200.9M
Long Term Capital Lease Obligation$2.1B
Current Debt$2.4B
Market Data
Exchange
HKEX
CurrencyUSD
CountryHong Kong
Last Updated2026-02-02
Disclaimer: Shariah screening is based on the latest available financial data. Market conditions and company activities may change. Always conduct your own due diligence.
HKEX
